Sign in
Taking people in United StatesNo phase

Amnion grafts for slow-healing diabetic foot ulcers and venous leg ulcers

Tests amnion grafts for slow-healing diabetic foot or leg ulcers.

Key facts

Who runs it
Capsicure, LLC
Where
Coral Gables, Houston, Indianapolis, Miami, Oxnard, St Louis, and Syosset, United StatesSee the 7 sites
Trial code
Registry title
CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations
Status
Recruiting
People taking part
165 people, planned
Started
1 Oct 2025
Planned end
20 Jul 2026
Type of study
Interventional, 3 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap
  • IP2: BioLab Tri-Membrane Wrap
Record updated
22 October 2025

Who can take part

The trial is looking for adults with a venous leg ulcer or diabetic foot ulcer that has not healed. It compares two amnion graft treatments.

Age
18 years and older
Sex
Male or female
Disease stage
The venous leg ulcer or diabetic foot ulcer has lasted more than 4 weeks. It shrank by less than 50% in the last 4 weeks. The wound is at least 2 cm2 and at most 25cm2. If there is more than one wound, the largest one is studied.
Earlier treatment
No treatment of the wound with engineered tissue or other scaffold materials within 30 days before the first treatment visit.
Main reasons for not taking part
  • Pregnancy or breastfeeding, or able to become pregnant without proper birth control
  • The wound shrank by 50% in the four weeks before joining
  • Wound infection that needs local or whole-body antimicrobials or antibiotics
  • Known reasons not to use amniotic tissue grafts
  • Other health problems that the study doctor thinks may make the trial unsafe
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Male or female 18 years of age and older
  • 2. Subjects having a non-healing venous leg ulcer or diabetic foot ulcer of >4 weeks duration and visible signs of healing objectively, less than 50% reduction in wound size in the last 4 weeks
  • Subjects' wound size is minimum of 2 cm2 and maximum of 25cm2
  • If the subject has more than one eligible wound the largest wound will be selected (the index wound)
  • Subject is able and willing to follow the protocol requirements
  • Subject has signed informed consent

Who cannot take part

  • Visible signs of improvement in the four weeks before randomisation (defined objectively as a 50% reduction in surface area in the four weeks before enrolment)
  • The subject has other concurrent conditions that in the opinion of the investigator may compromise subject safety
  • The index ulcer shows clinical signs and symptoms of wound infection needing treatment with local or systemic antimicrobials or antibiotics
  • Inability to adhere to the study protocol or study visit schedule
  • Pregnancy
  • Child-bearing potential without appropriate contraception
  • Lactation
  • Treatment of the wound with engineered tissue or other scaffold materials within 30 days preceding the first treatment visit
  • Known contraindications to the use of amniotic tissue grafts

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Diabetic foot ulcer or venous leg ulcer or wound; foot

This trial is currently available in United States.

  • Solutions Medical ResearchCoral Gables, United StatesContact: Liliana LorenzoTaking people
  • HOPE Vascular and PodiatryHouston, United StatesContact: Mariana BurnierTaking people
  • Indiana University Health Methodist HospitalIndianapolis, United StatesContact: Bryce HockmanTaking people
  • Nova Medical Services - Research Division LLCMiami, United StatesContact: Valmys OrtizTaking people
  • Fomat Medical ResearchOxnard, United StatesContact: Luis ParraTaking people
  • St. Louis Foot and Ankle, LLCSt Louis, United StatesContact: Bonnie ScaggsTaking people
  • Jevlos Health, IncSyosset, United StatesContact: Christopher InfantinoTaking people

About the trial

What the trial wants to find out

CAMP RWE Trial: A Multicenter hybrid platform trial comparing the effects of a prospective cohort treated with a tri-layer amnion graft or a single layer amnion graft to a coarsened exact matched retrospective control cohort of patients with hard-to-heal DFUs and VLUs

The 3 groups in the trial

  • Standard of CareNo study treatment, for comparison

    This study will employ a platform umbrella design in which two studies will be run: one for diabetic foot ulcers and one for venous leg ulcers. Each study will have two intervention groups and one common SOC group. Subjects will be randomized to one of two interventions: IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap Subjects in the control group will be drawn from deidentified data sourced from the US Wound Registry. The US Wound Registry (USWR) is recognized by CMS as a Qualified Clinical Data Registry (QCDR). The matching of intervention to control groups will use coarsened exact matching (CSM) in which key variables are used to match: e.g., age, sex, baseline wound area, baseline wound age. The desired control subject pool should be three times larger than the prospective group (at least 165 in wound type.)

  • IP1: BioLab Membrane Wrap LiteTreatment being tested

    This study will employ a platform umbrella design in which two studies will be run: one for diabetic foot ulcers and one for venous leg ulcers. Each study will have two intervention groups and one common SOC group. Subjects will be randomized to one of two interventions: IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap Subjects in the control group will be drawn from deidentified data sourced from the US Wound Registry. The US Wound Registry (USWR) is recognized by CMS as a Qualified Clinical Data Registry (QCDR). The matching of intervention to control groups will use coarsened exact matching (CSM) in which key variables are used to match: e.g., age, sex, baseline wound area, baseline wound age. The desired control subject pool should be three times larger than the prospective group (at least 165 in wound type.)

    Treatment: IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap

  • IP2: BioLab Tri-Membrane WrapTreatment being tested

    This study will employ a platform umbrella design in which two studies will be run: one for diabetic foot ulcers and one for venous leg ulcers. Each study will have two intervention groups and one common SOC group. Subjects will be randomized to one of two interventions: IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap Subjects in the control group will be drawn from deidentified data sourced from the US Wound Registry. The US Wound Registry (USWR) is recognized by CMS as a Qualified Clinical Data Registry (QCDR). The matching of intervention to control groups will use coarsened exact matching (CSM) in which key variables are used to match: e.g., age, sex, baseline wound area, baseline wound age. The desired control subject pool should be three times larger than the prospective group (at least 165 in wound type.)

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter Hybrid Platform Trial Comparing the Effects of a Prospective Cohort Treated With a Tri- Layer Amnion Graft or a Single Layer Amnion Graft to a Coarsened Exact Matched Retrospective Control Cohort of Patients With Hard-to-heal DFUs and VLUs
Plain-language title
Amnion grafts for slow-healing diabetic foot ulcers and venous leg ulcersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07046767, who can take part
Record updated
22 October 2025